度普利尤单抗:其在特应性皮炎治疗中的应用综述
度普利尤单抗是一种白细胞介素4受体α拮抗剂,通过阻断IL-4和IL-13信号发挥作用,已在欧美获批用于成人中重度特应性皮炎。临床试验显示,每周或每两周注射可显著改善临床与患者报告结局,联用外用糖皮质激素优于单药。常见不良事件为鼻咽炎、上呼吸道感染、注射部位反应、皮肤感染和结膜炎,多为轻中度,治疗组与安慰剂组总体不良事件频率相似。
要点
- 度普利尤单抗阻断IL-4/IL-13信号,降低Th2免疫反应。
- 每周或每两周注射可显著改善EASI、SCORAD、DLQI和瘙痒NRS评分。
- 联用外用糖皮质激素对症状改善优于度普利尤单抗单药。
核心结论
- 度普利尤单抗单药或联用外用糖皮质激素可显著改善中重度特应性皮炎患者的临床结局和生活质量。
- 正在进行的度普利尤单抗研究将有助于确定其长期使用的临床疗效和安全性特征。
研究设计与样本
- 综述,总结度普利尤单抗在特应性皮炎治疗中的使用,涵盖作用机制、临床试验结果和生物标志物分析。
主要发现
- 临床试验显示,接受每周或每两周度普利尤单抗注射的成人中重度特应性皮炎患者,包括湿疹面积严重度指数、特应性皮炎评分、皮肤病生活质量指数和瘙痒数字评定量表在内的临床与患者报告结局显著改善。
- 与度普利尤单抗单药相比,联用外用糖皮质激素使特应性皮炎体征和症状改善更大。
- 生物标志物分析显示度普利尤单抗调节特应性皮炎分子特征和其他Th2相关生物标志物。
- 临床试验报告的常见不良事件为鼻咽炎、上呼吸道感染、注射部位反应、皮肤感染和结膜炎,这些不良事件为轻中度,治疗组与安慰剂组总体不良事件发生率相似。
- III期临床试验未发现显著的严重安全性问题。
关键数值与推荐
- 度普利尤单抗是一种白细胞介素4受体α拮抗剂,通过阻断共享的IL-4α亚基抑制IL-4和IL-13信号。
- 度普利尤单抗最近在美国和欧洲获批用于成人中重度特应性皮炎的治疗。
临床怎么用
- 度普利尤单抗单药或联用外用糖皮质激素可用于显著改善中重度特应性皮炎患者的临床结局和生活质量。
局限性
- 原文提及正在进行的度普利尤单抗研究将有助于确定其长期使用的临床疗效和安全性特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atopic dermatitis (AD) is a chronic, pruritic immune-mediated inflammatory dermatosis characterized by a T helper 2 (Th2) immune response phenotype and may be associated with systemic inflammation. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4α subunit. Blockade of IL-4/13 is effective in reducing Th2 response. Dupilumab has recently been approved in the United States and Europe for the treatment of adult patients with moderate-to-severe AD. Clinical trials have shown that adults with moderate-to-severe AD who receive weekly or biweekly dupilumab injections have significantly improved clinical and patient-reported outcomes, including Eczema Area Severity Index, SCORing Atopic Dermatitis, Dermatology Life Quality Index, and itch Numeric Rating Scale scores. Concomitant use of topical corticosteroids along with dupilumab results in a greater improvement in signs and symptoms of AD than with use of dupilumab alone. Biomarker analyses show that dupilumab modulates the AD molecular signature and other Th2-associated biomarkers. Common adverse events reported in the clinical trials were nasopharyngitis, upper respiratory tract infection, injection site reactions, skin infections, and conjunctivitis. These were mild-to-moderate in nature, and overall rates of adverse events occurred with similar frequency between the treatment and placebo groups. There were no significant serious safety concerns identified in phase III clinical trials. Dupilumab, as monotherapy or with concomitant use of topical corticosteroids, can significantly improve clinical outcomes and quality of life in patients suffering from moderate-to-severe AD. Ongoing studies of dupilumab will help determine the clinical efficacy and safety profile of its long-term use.
引用
- Gooderham MJ, Hong HC, Eshtiaghi P, et al. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018. PMID: 29471919. doi:10.1016/j.jaad.2017.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。